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Fructose intake has increased substantially throughout the developed world and is associated
with obesity, type 2 diabetes and non-alcoholic fatty liver disease. Currently, our under-
standing of the metabolic and mechanistic implications for immune cells, such as monocytes
and macrophages, exposed to elevated levels of dietary fructose is limited. Here, we show
that fructose reprograms cellular metabolic pathways to favour glutaminolysis and oxidative
metabolism, which are required to support increased inflammatory cytokine production in
both LPS-treated human monocytes and mouse macrophages. A fructose-dependent
increase in mTORC1 activity drives translation of pro-inflammatory cytokines in response
to LPS. LPS-stimulated monocytes treated with fructose rely heavily on oxidative metabolism
and have reduced flexibility in response to both glycolytic and mitochondrial inhibition,
suggesting glycolysis and oxidative metabolism are inextricably coupled in these cells. The
physiological implications of fructose exposure are demonstrated in a model of LPS-induced
systemic inflammation, with mice exposed to fructose having increased levels of circulating
IL-1β after LPS challenge. Taken together, our work underpins a pro-inflammatory role for
dietary fructose in LPS-stimulated mononuclear phagocytes which occurs at the expense of
metabolic flexibility.
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Typically, activation of the human innate immune systemrequires the rewiring of cellular metabolic pathways largelyto favour glucose metabolism1–5. However, in the various
nutrient environments they inhabit, monocytes will be exposed to
a range of different carbon sources, the availability of which will
likely dictate their metabolism and phenotype. One such carbon
source is fructose, the second most abundant dietary sugar found
in humans. Fructose is metabolised by glycolysis either by keto-
hexokinase producing fructose-1-phosphate, a substrate for
aldolase B6 (in the liver, kidneys and intestines for example) or
converted to the glycolytic intermediate fructose-6-phosphate by
hexokinase (HK), albeit at a lower rate than glucose7,8.
Fructose intake has increased substantially throughout the
Western world, largely attributed to elevated sucrose and high
fructose corn syrup consumption9 and is thought to exacerbate
various non-communicable conditions such as obesity, type 2
diabetes and non-alcoholic fatty liver disease9. Chronic fructose
consumption in these conditions has recently been shown to
drive hepatic fructolysis, where the expression of lipogenic genes
is enhanced10–12.
Typically, physiological levels of fructose in the circulation
range from 0.04 to 0.2 mM13; however, there are several patho-
physiological scenarios in which levels of fructose are elevated. For
example, peripheral blood levels can exceed 1mM in patients with
haematological malignancies such as acute myeloid leukaemia and
acute lymphoblastic leukaemia14. In addition, fructose con-
centrations in the bone marrow microenvironment of haemato-
logical cancer patients can reach up to 5 mM14. Alterations in the
glucose to fructose ratio, particularly when glucose is scarce,
enables acute myeloid leukaemia blasts to significantly enhance
fructose uptake14. Localised mouse tissue microenvironments,
such as the liver, kidneys and jejunum, also have elevated levels of
fructose metabolism15. Therefore, there are various pathophysio-
logical scenarios and tissue microenvironments where monocytes
will be exposed to either equimolar concentrations of fructose and
glucose or concentrations of fructose exceeding that of glucose.
The impact of elevated fructose exposure on the immune
system has not been investigated extensively. Chronic fructose
exposure in rats results in a more inflammatory phenotype of
bone marrow mononuclear cells16. While there is some evidence
that lipopolysaccharide (LPS)-stimulated human dendritic cells
are able to produce enhanced levels of pro-inflammatory cyto-
kines when cultured in fructose as opposed to glucose, the
underlying metabolic rewiring that enables this pro-inflammatory
phenotype has not been investigated17.
Here we characterise how human monocytes and mouse
macrophages respond metabolically and functionally to fructose
exposure. We show that activated mononuclear phagocytes
demonstrate plasticity in engaging metabolism of this alternative
carbon source, yet it leaves the cells metabolically inflexible and
vulnerable to further metabolic challenge. Fructose exposure
reprogrammes cellular pathways to favour glutaminolysis and
oxidative metabolism, which support an inflammatory phenotype
in both human and mouse mononuclear phagocytes. Finally, we
demonstrate that a short-term high fructose diet promotes
inflammation in vivo, suggesting that our findings have patho-
physiological significance.
Results
Fructose exposure promotes an oxidative phenotype. We
sought to investigate the metabolic response to fructose exposure
in activated human monocytes in comparison to other mono-
saccharides (glucose and galactose) or complete sugar withdrawal.
Galactose has been used previously to promote oxidative phos-
phorylation (OXPHOS) in T cells by reducing glycolysis18. Using
the Seahorse Bioanalyzer, we initially injected the mono-
saccharide (glucose, fructose or galactose) or media control
containing no sugar. After 1 h, monocytes were stimulated with
LPS and the corresponding extracellular acidification rate
(ECAR) and oxygen consumption rate (OCR) were used to
measure glycolysis and OXPHOS, respectively, for the duration.
Monocytes incubated with glucose demonstrated a robust
increase in basal and LPS-induced ECAR (Fig. 1A). By contrast,
monocytes treated with fructose or galactose had low baseline
levels of glycolysis, only slightly greater than no sugar controls
(Fig. 1A). In addition, monocytes treated with fructose, galactose
or no sugar had only a modest increase in ECAR post-LPS
exposure (Fig. 1A). Upon activation, glucose-treated cells reduced
their OCR, consistent with the reported metabolic switch from
OXPHOS to glycolysis upon activation3. Monocytes treated with
fructose, galactose or no sugar had an initial burst of increased
oxygen consumption and maintained higher OCR for the
duration of the assay (Fig. 1B). This demonstrates metabolic
flexibility of human monocytes, in this case towards OXPHOS
when the cells are unable to engage in glycolysis.
After the introduction of 2-deoxy-D-glucose (2-DG), ECAR
was reduced in all conditions (Fig. 1C). OCR was increased in
glucose-treated monocytes, a compensatory response to glycolysis
inhibition, whereas in fructose, galactose or no sugar treatment a
decrease in OCR was observed (Fig. 1D). These data suggest that
LPS-stimulated monocytes treated with fructose or galactose
direct pyruvate towards the mitochondrial tricarboxylic acid
(TCA) cycle for OXPHOS, whereas glucose treatment directs
pyruvate towards lactate production. We confirmed extracellular
levels of lactate are indeed reduced in fructose compared to
glucose-treated monocytes (Supplementary Fig. 1A). This diver-
gence appears to account for the differences in OXPHOS rates
observed. Overall, LPS-stimulated human monocytes treated with
fructose maintained an elevated oxidative phenotype with low
ECAR, akin to galactose or no sugar treatment, whereas glucose
availability preferentially maintained elevated levels of glycolysis
at the expense of reduced oxygen consumption (Fig. 1E).
In agreement with a previous study, LPS-stimulated monocytes
cultured for 24 h with galactose or no sugar had a significant
reduction in viability in comparison to the glucose-treated control
(Fig. 1F)19. However, we observed no difference in viability
between glucose and fructose treatment (Fig. 1F).
To further elaborate fructose metabolism in LPS-stimulated
monocytes, we incubated them with either uniformly labelled
13C6-fructose or 13C6-glucose and performed stable isotope tracer
analysis (SITA). Activated monocytes were able to transport
fructose into the cell (presumably via GLUT5 expression—
Supplementary Fig. 1B) and incorporated comparable levels of
carbon into intracellular lactate while increasing incorporation
into TCA cycle intermediates and amino acids in comparison to
glucose (Supplementary Fig. 1C–E). These results suggest that the
cells have the ability to metabolise fructose carbon and use it in
the TCA cycle.
Collectively, these data reveal that fructose treatment promotes
a low glycolytic rate without compromising cell viability. This
demonstrates the metabolic flexibility of human monocytes as
well as their ability to utilise an alternative carbon source.
Glycolysis and OXPHOS are coupled in fructose-treated
human monocytes. To confirm that the observed increase in
OCR in fructose-treated monocytes was due to OXPHOS as
opposed to an increase in other oxygen-consuming processes, we
utilised the ATP synthase inhibitor, oligomycin. Here, monocytes
were treated with either glucose or fructose and allowed to rest
prior to LPS exposure. Oligomycin was later injected and the
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bioenergetic changes were monitored over time. While OCR of
both glucose or fructose LPS-simulated monocytes decreased to
the same level upon oligomycin treatment (Fig. 2A), the drastic
reduction of OCR in fructose-cultured monocytes reflects a
greater reliance on OXPHOS. Cells reliant on OXPHOS may
demonstrate metabolic flexibility upon oligomycin treatment by
increasing glycolysis. However, surprisingly, ECAR in fructose-
cultured monocytes decreased in response to oligomycin, sug-
gesting the lack of metabolic adaptation in these cells (Fig. 2B, C).
Secondly, to establish whether the elevated ECAR levels post-
LPS treatment reflected glycolytic activity as opposed to other
acidifying processes, we used a lactate dehydrogenase inhibitor
(GSK2837808A; LDHi). Here, the increased ECAR in response to
LPS stimulation was reduced in glucose-treated monocytes upon
LDHi treatment (Fig. 2D). By contrast, LDHi modestly impacted
ECAR in fructose-treated cells, arguing that fructose-mediated
glycolysis is coupled to OXPHOS. The low level of ECAR under
this condition is most likely due to acidification of the media by
an alternative source to lactate (Fig. 2D). We confirmed this was
not due to changes in LDH phosphorylation in fructose- versus
glucose-treated cells (Supplementary Fig. 1F).
The corresponding OCR levels increased in the glucose-treated
monocytes upon LDHi treatment as pyruvate is directed towards
OXPHOS, again demonstrating the bioenergetic flexibility of human
monocytes. By contrast, OCR in fructose-treated monocytes
remained unchanged for the duration of the assay (Fig. 2E, F).
These data further demonstrate that glycolysis and OXPHOS are
tightly coupled in fructose-treated cells, revealing impaired meta-
bolic flexibility in comparison to glucose-treated cells (Fig. 2C, F).
Fructose treatment enhances LPS-induced inflammation.
Given the distinct metabolic characteristics of human monocytes
exposed to fructose (Fig. 1A), we were intrigued to investigate the
impact on monocyte function. Fructose-treated monocytes pro-
duced elevated levels of a panel of secreted cytokines, namely
interleukin-1β (IL-1β), IL-6, IL-8, IL-10 and tumour necrosis
factor (TNF) (Fig. 3A–E), with IL-1β, IL-8, IL-10 and TNF
reaching statistical significance in comparison to glucose treat-
ment. Despite elevated levels of cytokine secretion, there were no
differences in various surface markers associated with monocyte
activation (HLA-DR, CD80, CD86, CD62L, CCR5 and CCR2)
between the glucose- or fructose-treated monocytes (Supple-
mentary Fig. 2A).
To determine whether the increased production of cytokines
was a consequence of increased transcription, we performed
Fig. 1 Fructose mimics a metabolic profile akin to nutrient restriction. A Seahorse extracellular flux analysis of ECAR in monocytes before and following
injections of glucose, fructose, galactose (11.1 mM) or no sugar, LPS (10 ng/mL) and 2-DG (100mM) at the time points indicated with average basal (Av.
basal) and LPS-stimulated (Av. LPS) ECAR values. B Analysis of OCR in monocytes with the same injections as in panel (A), including average basal (Av.
basal) and LPS-stimulated (Av. LPS) OCR values. C Change in ECAR (Δ ECAR) post 2-DG treatment. D Change in OCR (Δ OCR) post 2-DG treatment.
E OCR versus ECAR map of average basal and LPS-stimulated values for glucose, fructose, galactose and no sugar treatment groups. Arrows indicate the
shift in metabolism from average basal to average LPS. F Representative flow cytometry plot and DRAQ7 viability measurements of glucose, fructose,
galactose and no sugar monocytes cultured for 24 h with LPS (10 ng/mL). Statistical significance was assessed using a one-way ANOVA with Dunnett’s
(A–D) or Tukey’s (F) multiple comparisons test. Data are either representative of either three (A–E) or four independent experiments (F). Data are
expressed as mean ± SEM; ***p≤ 0.001. Source data are provided as a Source Data file.
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RNA-sequencing (RNA-seq) analysis of LPS-stimulated mono-
cytes treated with glucose or fructose. Surprisingly, we observed
only five genes that were significantly changed between the two
conditions, with no alteration to transcript levels for the cytokines
of interest (Supplementary Fig. 2B). Consistent with this, the
expression level of genes encoding cytokines was also comparable
in monocytes treated with either glucose or fructose (Fig. 3F),
suggesting that the increased cytokine production was not
through transcriptional regulation. Fructose has recently been
reported to activate mTORC1 via dihydroxyacetone phosphate
sensing20. Consistent with this, phosphorylation of the down-
stream mTORC1 target, S6 ribosomal protein, was elevated
significantly in LPS-stimulated monocytes treated with fructose
(Fig. 3G). Of note, we observed no differences in the induction of
AMPK (AMP-activated protein kinase) signalling between the
two groups (Supplementary Fig. 2C). Collectively, these observa-
tions demonstrate that LPS stimulation in the presence of fructose
enhances inflammatory cytokine production, in part, through
increased mTORC1-mediated translation.
Fructose treatment drives a sustained oxidative phenotype.
LPS-stimulated monocytes in the presence of fructose clearly
enhance oxygen consumption in the short term (Fig. 1C). Next,
we wanted to determine whether heightened oxygen consump-
tion was sustained long term in activated monocytes. Here, using
the Seahorse Bioanalyzer, we performed a mitochondrial stress
test with a final injection of the ionophore, monensin21, following
a 24-h incubation period with either glucose or fructose. Elevated
levels of oxygen consumption were indeed sustained long term in
fructose-treated LPS-stimulated monocytes (Fig. 4A). This was
characterised by increased levels of oxidative parameters such as
basal respiration, ATP-linked respiration and a higher percentage
of coupling efficiency in comparison to glucose (Fig. 4B–D and
Supplementary Fig. 3A–D). Corresponding ECAR levels were
unsurprisingly higher in glucose-treated monocytes in compar-
ison to fructose-treated cells (Fig. 4E, F and Supplementary
Fig. 3E). Notably, fructose-treated monocytes had a significantly
higher ratio of basal OCR/ECAR ratio in comparison to glucose,
indicating their commitment to oxidative metabolism (Fig. 4G).
We next assessed the contributions of glycolysis derived- and
OXPHOS-derived ATP production21. These analyses show
glucose-treated monocytes as glycolytic cells functioning at their
maximal glycolytic ATP production rate at baseline (Fig. 4H). At
maximal bioenergetic capacity, they demonstrate flexibility
towards ATP production from OXPHOS, but still derive the
majority of their ATP from glycolysis and therefore remain
classed as glycolytic cells (Fig. 4H and Supplementary Fig. 3F, G).
By contrast, fructose-treated monocytes are oxidative (deriving
the majority of their ATP from OXPHOS) at baseline and this
phenotype is further exacerbated when cells are at maximal
bioenergetic capacity (Fig. 4H and Supplementary Fig. 3F, G).
They do, however, have some metabolic scope to increase ATP
production from glycolysis (Fig. 4H).
We reasoned that differential mitochondrial properties might
explain the heightened oxidative phenotype of fructose-treated
monocytes. However, we observed no difference in mitochondrial
content (MitoTracker Green), membrane potential (tetramethylr-
hodamine ethyl ester) or mitochondrial-derived reactive oxygen
species (ROS) (Fig. 4I). Further to this, we also assessed levels of the
individual respiratory complexes by immunoblot. Again, we
observed no difference in the abundance of complexes I–IV
between fructose- or glucose-treated monocytes (Fig. 4J). A high
fructose diet has been shown to increase de novo lipogenesis in the
liver10. This correlates with increased mitochondrial ATP produc-
tion, which may support this energy-demanding process22,23.
Fig. 2 Fructose treatment enhances oxidative metabolism. Seahorse extracellular flux analysis of A OCR and B ECAR in monocytes before and following
injections of glucose or fructose (both 11.1 mM), LPS (10 ng/mL) and oligomycin (1 µM) at the time points indicated. C OCR versus ECAR map of average of
a single value pre- and post-oligomycin injection for glucose- and fructose-treated monocytes. Arrows indicate the shift in metabolism upon inhibitor
exposure. Analysis of D ECAR and E OCR in monocytes as A with a final injection of a lactate dehydrogenase inhibitor (GSK2837808A, LDHi; 10 µM).
F OCR versus ECAR map as C with pre- and post- LDHi injection. Data are representative of three independent experiments and are expressed as mean ±
SEM. Source data are provided as a Source Data file.
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Therefore, a potential explanation for the elevated ATP-linked
respiration observed is that fructose-treated monocytes are
supporting a higher level of lipogenesis. We observed no differences
in phosphorylation of enzymes that catalyse the citrate-derived fatty
acid synthesis steps; ATP citrate lyase (ACLY) or acetyl-CoA
carboxylase (Supplementary Fig. 3H). However, fructose-cultured,
LPS-stimulated monocytes have increased levels of the lipid
mediator, prostaglandin E2 and greater sensitivity to the ACLY
inhibitor, BMS303141, with regards to cytokine production
(Supplementary Fig. 3I, J). Taken together, these data demonstrate
that fructose treatment elevates ATP-linked oxygen consumption,
independent of mitochondrial ROS and content.
Fructose increases TCA cycling and anaplerosis. To further
characterise the metabolic activity of the mitochondria in glucose-
and fructose-treated cells, we used SITA coupled with gas
chromatography-mass spectrometry (GC-MS). Here, human
monocytes were activated with LPS for 24 h and incubated with
either 13C6-glucose or 13C6-fructose (Fig. 5A). Mass isotopologue
distribution (MID) analysis of the TCA cycle intermediates—
succinate, fumarate and malate—and amino acids—glutamate
and aspartate—highlighted that there was increased cycling in the
fructose-cultured monocytes compared to glucose. This was
indicated by a reduced proportion of the unlabelled form of the
metabolite (m+ 0) and an increased proportion of the labelled
form (predominantly represented by m+ 2) (Fig. 5B, C and
Supplementary Fig. 4A).
The TCA cycle relies on other metabolites to replenish it, a process
termed anaplerosis. Glutamine-derived carbon enters the TCA cycle
and also contributes to TCA-mediated amino acid biosynthesis, such
as aspartate. To investigate whether fructose treatment increases
glutamine anaplerosis, we performed SITA with 13C5-glutamine.
Here, monocytes were incubated with 13C5-glutamine in the
presence of either glucose or fructose and activated with LPS
(Fig. 5C). The ass isotopologue distribution analysis of the TCA cycle
metabolites—succinate, fumarate and malate—demonstrated an
increase in the percentage of 13C into these intermediates in the
presence of fructose (represented as m+ 4) (Fig. 5D and
Supplementary Fig. 4B). Fructose-treated monocytes are able to
incorporate elevated amounts of glutamine-derived carbon to the
TCA cycle intermediates and amino acids in comparison to glucose-
treated monocytes (Supplementary Fig. 4C–G). These data demon-
strate that fructose treatment increases the proportion of both sugar
and glutamine carbon into the TCA cycle to support the observed
increased rates of OXPHOS.
Fructose-treated human monocytes are vulnerable to metabolic
challenge. Thus far, we have demonstrated that fructose treat-
ment promotes a reduced glycolytic rate and enhanced OXPHOS.
Glucose and fructose are both metabolised by the enzyme HK,
producing metabolites glucose 6-phosphate or fructose-6-
phosphate respectively24. Therefore, we sought to investigate
the expression levels of the two predominant isoforms of HK:
HKI and HKII. We observed no difference in expression levels of
HKI; however, HKII levels were increased in fructose-treated,
LPS-stimulated monocytes, in comparison to glucose (Fig. 6A, B).
To further delineate the role of HK in monocyte function, we
utilised the HK inhibitor, 2-DG. We treated activated monocytes
in glucose or fructose for 24 h with 2-DG before measuring
cytokine production. Following treatment with 2-DG, production
of IL-1β, IL-6 and TNF was largely unaffected in glucose-treated
cells, with the exception of IL-10. By contrast, fructose-treated
Fig. 3 Fructose promotes a more inflammatory phenotype. Extracellular cytokine release of A IL-1β, B IL-6, C IL-8, D IL-10 and E TNF. F Heatmaps
displaying the normalised read counts of selected cytokines from RNA-seq analysis of monocytes treated with glucose or fructose (both 11.1 mM)
stimulated with LPS (10 ng/mL) for 24 h. G Representative immunoblot and pooled data of downstream mTOR target pS6 with housekeeping control, actin.
Statistical significance was assessed using a one-sample t test (A–E) or an unpaired, two-tailed t test (G). Data are representative of five (A, B, D, E), four
(C), three (F) and six independent experiments (G) and are expressed as mean ± SEM. Source data are provided as a Source Data file.
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cells exhibited a dose-dependent decrease in all cytokines
(Fig. 6C).
Having shown that 2-DG treatment reduced OXPHOS in
fructose-treated cells (Fig. 1D), these results suggest the oxidative
metabolic phenotype induced by fructose supports monocyte
function. Given the enhanced reduction of cytokine expression, we
next determined the level of cell viability for 2-DG-treated
monocytes. Fructose-treated monocytes were acutely sensitive to
2-DG-mediated cell death in comparison to glucose-treated
monocytes that were largely unaffected (Fig. 6D). We next wanted
to assess whether the cells were similarly sensitive to inhibition of
oxidative metabolism. The viability of LPS-stimulated monocytes
treated with glucose was minimally affected by inhibition of
complex I (with rotenone), III (with antimycin A) and V (with
oligomycin). However, monocytes treated with fructose were
completely unable to tolerate incubation with these drugs,
reflected by a striking reduction in viability (Fig. 6E). These data
demonstrate that fructose treatment renders LPS-stimulated
monocytes metabolically inflexible and dependent on oxidative
metabolism. Sensitivity to both 2-DG and mitochondrial inhibi-
tors suggest that glycolysis and oxidative metabolism become
inextricably coupled upon exposure to fructose.
Fig. 4 Fructose-induced oxidative phenotype is maintained in LPS-stimulated monocytes. AMitochondrial stress assay of monocytes cultured for 24 h in
the presence of glucose or fructose (both 11.1 mM) and activated with LPS (10 ng/mL). Corresponding OCR measured with injections of oligomycin (1 µM),
FCCP (3 µM), antimycin A (1 µM) and rotenone (1 µM) and monensin (20 µM). Respective mitochondrial parameters B basal respiration, C ATP-linked
respiration and D coupling efficiency calculated via ATP-linked respiration/basal respiration. E Equivalent ECAR rate measured with f basal glycolysis
levels. G OCR/ECAR ratio calculated by basal respiration/basal glycolysis levels. H Bioenergetic scope examining the ATP production (JATP) of oxidative
phosphorylation versus glycolysis of basal and maximal of glucose or fructose. Mitochondrial parameters i Content: MitoTracker Green (MTG), membrane
potential: tetramethylrhodamine ethyl ester (TMRE) and mitochondrial-derived ROS: MitoSOX measured by flow cytometry. J Mitochondrial respiratory
complex (I–V) assessment by western blot. Statistical significance was assessed using an unpaired, two-tailed t test (B–D, F–B). Data are representative of
four (A–H, J) or three (I) independent experiments. Data are expressed as mean ± SEM. Source data are provided as a Source Data file.
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Dietary fructose increases inflammation in a mouse model.
Thus far, we have explored the metabolic and mechanistic impli-
cations of fructose exposure in human monocytes cultured ex vivo.
In order to further investigate the impact of physiological fructose
exposure on inflammation in vivo, we employed a mouse model.
First, we determined whether mouse LPS-challenged bone marrow-
derived macrophages (BMDMs) phenocopied human monocytes
when exposed to fructose in vitro.
To better recapitulate the in vivo microenvironment, we
incubated mouse macrophages with either glucose alone or a 1:1
ratio of glucose to fructose (maintaining the equivalent
concentration of total monosaccharide). This strategy has been
used previously in several studies to investigate the physiological
impact of fructose exposure in an environment when glucose is
also present10,15,25. Consistent with human monocytes, LPS-
stimulated mouse macrophages exposed to fructose produced
elevated levels of cytokines TNF, IL-1β, IL-6 and IL-12 at the
protein level, but not the messenger RNA level in comparison to
glucose alone (Fig. 7A and Supplementary Fig. 5A, B).
Importantly, we demonstrated that this observation is not due
to reduced glucose availability in the double monosaccharide
condition (Supplementary Fig. 5C).
In order to confirm fructose uptake in the presence of glucose,
we performed SITA analysis using mouse macrophages cultured
in universally labelled 13C6-glucose alone or 13C6-glucose with
13C1-fructose (Fig. 7B). Indeed, fructose enters the cells in the
presence of glucose as depicted by the presence of the m+ 1
isotopologue (Fig. 7C). Similar to human monocytes, BMDMs
exposed to fructose significantly increased glutamine uptake and
phosphorylation of the mTORC1 target, S6 ribosomal protein
(Fig. 7D, E). Fructose treatment also led to an increase in Akt
phosphorylation (Supplementary Fig. 5D).
Next, we investigated the role of glutamine metabolism in
fructose-treated mouse macrophages and their response to LPS.
The glutaminase inhibitor CB-839 did not alter levels of TNF;
however, it significantly reduced IL-1β and IL-12 in BMDMs
cultured in the presence of both monosaccharides, whereas
cytokine production was unchanged in cells cultured with glucose
alone (Fig. 7F). CB-839 also reduced phosphorylation of S6 in
fructose-exposed cells (Supplementary Fig. 5E), suggesting that
increased glutamine metabolism supports mTORC1 activity in
the presence of fructose. Further exploring the role of mTORC1
in fructose-mediated inflammation, we treated BMDMs with the
mTORC1 inhibitor, rapamycin. Here, rapamycin treatment
significantly reduced cytokine production in both glucose-alone
and glucose–fructose-treated macrophages (Fig. 7G). These data
suggest that mouse macrophages require mTORC1 activity for
cytokine production regardless of sugar exposure, yet those
exposed to both monosaccharides (in contrast to those exposed to
glucose alone) rely on glutaminolysis to support the increased
cytokine production promoted by fructose exposure.
Finally, to determine if fructose supplementation can influence
LPS-induced inflammation in vivo, we used a mouse LPS model of
systemic inflammation. Here, mice were provided 10% glucose or
10% fructose/10% glucose solutions for 2 weeks (to preclude
development of any metabolic disorders) prior to LPS challenge
(Fig. 7H). Strikingly, serum IL-1β levels were significantly increased
in mice exposed to fructose, and an increasing trend of IL-6 and
TNF was observed (Fig. 7I). This increase in serum IL-1β was not
due to fructose-enhancing baseline IL-1β secretion, as seen at weeks
1 and 4 of sugar-water treatment in unchallenged mice (Supple-
mentary Fig. 6A, B).
Interestingly, the presence of fructose does not result in a
global increase in serum inflammatory markers, as while levels of
CXCL5 were elevated in the presence of fructose, this did not
reach statistical significance and there was no change in CXCL1
and CCL11 (Supplementary Fig. 6C–E). These data demonstrate
that short-term fructose supplementation enhances LPS-induced
systemic inflammation, suggesting physiological repercussions of
high fructose exposure in mammals.
Fructose-supported inflammation does not occur in T cells.
Given our results of an effect of fructose on both human and
mouse mononuclear phagocytes, we were intrigued as to whether
fructose exposure might have an effect on other immune
cell types. However, functional observations of heightened
Fig. 5 Fructose treatment induces elevated metabolic cycling. A Stable isotope tracing of uniformly labelled 13C-glucose or 13C-fructose into the TCA
cycle. B Mass isotopologue distribution (MID) represented as a % pool of TCA cycle metabolites: succinate, fumarate and malate or C amino acids:
glutamate and aspartate of 24-h LPS-stimulated monocytes. Numbers on the x-axis represent the number of 13Carbons incorporated. D Stable isotope
tracing of uniformly labelled 13C-glutamine in the presence of 12C-glucose or 12C-fructose of 24-h LPS-stimulated monocytes. EMID of succinate, fumarate
and malate and F amino acids: glutamate and aspartate. Statistical significance of individual mass isotopomers was assessed using an unpaired, two-tailed t
test (B, C, E, F). Data are representative of four independent experiments and are expressed as mean ± SEM. Source data are provided as a Source Data file.
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Fig. 6 Fructose-induced inflammatory monocytes are sensitive to metabolic inhibition. Immunoblot of LPS-stimulated monocytes in the presence of
glucose or fructose with A hexokinase I or B hexokinase II analysed. C Cytokine release (% of control) of IL-1β, IL-6, IL-10 and TNF (dotted line indicates
control) and D representative flow cytometry plot including DRAQ7 viability of glucose or fructose LPS-stimulated monocytes in the presence or absence
of glycolytic inhibitor, 2-DG (0.1 or 1.0 mM). E Representative flow cytometry plot including DRAQ7 viability of glucose or fructose LPS-stimulated
monocytes in the presence or absence of complex I inhibitor, rotenone (1 µM), complex III inhibitor antimycin A (1 µM) or complex V inhibitor, oligomycin
(1 µM). Statistical significance was assessed using an unpaired, two-tailed t test (A, B) or a two-way ANOVA with Sidak’s multiple comparison test (C, D).
Data are representative of five (A), four (B), three–four (C), three (D) or two independent experiments (E) and are expressed as mean ± SEM; *p≤ 0.05,
**p≤ 0.01 and ***p≤ 0.001. Source data are provided as a Source Data file.
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inflammation were not reflected in the mouse T cell compart-
ment. We did not observe any differences in CD4+ or CD8+ T
cell proliferation (Supplementary Fig. 7A). CD4+ T cells can be
programmed into inflammatory subsets, such as T-helper type 1
(Th1) or anti-inflammatory subsets such as inducible regulatory
T cells. Fructose supplementation did not influence polarisation
of either Th1 or inducible regulatory T cells (Supplementary
Fig. 7B, C). This suggests that fructose has a specific effect on
LPS-stimulated mononuclear phagocytes.
Discussion
Here, we investigate how activated human monocytes and mouse
macrophages respond metabolically and functionally to fructose
exposure. We demonstrate that mononuclear phagocytes from
both species are metabolically plastic in engaging in the meta-
bolism of an alternative carbon source and reprogramme cellular
pathways to favour oxidative metabolism. Although able to rewire
their metabolic pathways upon exposure to fructose, the cells are
left metabolically inflexible and vulnerable to further metabolic
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challenge. Importantly, we show that fructose exposure ex vivo
promotes elevated cytokine production in both human and
mouse mononuclear phagocytes and that a high fructose diet
promotes an inflammatory phenotype in vivo, attributing
pathophysiological relevance to our findings.
To date, most research has focused on the role of the dis-
accharide sucrose (glucose and fructose) in macrophage function.
Sucrose stimulates pinocytosis in unstimulated macrophages and
is broken down in the lysosome26. The only link to date between
fructose and macrophage-mediated inflammation is that supra-
physiological concentrations of sucrose (300 mM) enhance IL-1β
secretion, most likely due to hypertonicity27. There is some evi-
dence that fructose enhances myeloid function, either by
increasing cytokine production in human dendritic cells or pha-
gocytosis in mouse alveolar macrophages; however, the metabolic
mechanisms of fructose-mediated inflammation have not been
explored17,28. Coupled with this is a growing concern regarding
high fructose corn syrup consumption globally—in some cases,
accounting for 10% caloric intake in the USA29—thus under-
scoring the need to understand the implications of fructose
exposure on macrophage function and inflammation.
Here, for the first time, we show that LPS-stimulated human
monocytes and mouse macrophages exposed to fructose have an
enhanced inflammatory phenotype supported by oxidative
metabolism and glutaminolysis. We suggest this supports cyto-
kine production through increased supply of biosynthetic inter-
mediates. Mechanistically, we demonstrate that fructose-exposed
cells have increased mTORC1 activity, and while this is required
to support cytokine production regardless of sugar exposure,
those cells exposed to fructose rely specifically on glutaminolysis
to support their inflammatory phenotype (Fig. 7J). mTORC1 has
previously been implicated in metabolic reprogramming in
monocytes, with monocyte-specific deletion of Raptor (an
mTORC1 scaffolding protein) leading to reduced oxidative
metabolism during monocyte differentiation30. mTORC1 has also
been shown to be activated by glutaminolysis and α-ketoglutarate
production31. This is consistent with our findings and further
suggests that mTORC1 can act both upstream and downstream of
metabolic reprogramming.
We demonstrate that fructose-dependent metabolic repro-
gramming is maintained long term, but this is independent of
changes to mitochondrial dynamics. Instead, it appears due to
increased metabolic intermediate supply. Our data show that
fructose carbon can contribute to both glycolysis and the TCA
cycle, and whether this is mediated by HK or ketohexokinase
in both human and mouse mononuclear phagocytes requires
further exploration. In comparison to glucose, fructose-derived
pyruvate is not converted to lactate. This could be due to reduced
activity or expression of LDH (although our data would suggest
otherwise), increased activity of pyruvate dehydrogenase and
mitochondrial pyruvate carrier 1 or decreased activity of pyruvate
dehydrogenase kinase 132,33. Fructose exposure has also been
linked extensively to lipid biosynthesis, for example, fructose as a
substrate is 30% more efficient at synthesising fatty acids than
glucose, a phenomenon that has been implicated in the patho-
physiology of non-alcoholic fatty liver disease34,35. Consistent
with this, cytokine production was more sensitive to ACLY
inhibition and levels of prostaglandin E2 were elevated in our
fructose-treated monocytes.
It is clear that fructose levels fluctuate throughout health and
disease. With the increased prevalence of high fructose diets in the
Western world, understanding the impact of fructose on human
health is critical. Fructose contributes to numerous metabolic
disorders such as obesity, cancer and non-alcoholic fatty liver
disease; however, to date, our understanding of its impact on the
immune system is lacking9,36,37. A key strength of our study is the
assessment of the impact of fructose on metabolism and inflam-
mation across the two species. Akin to human monocytes, mouse
macrophages increased consumption of glutamine, produced
higher levels of cytokine production displayed and demonstrated
elevated mTORC1 activity. A mouse model of LPS-induced
inflammation allowed us to assess the physiological relevance of
our findings. Previous in vivo studies of long-term high fructose
exposure have been in the context of metabolic disorders such as
steatosis and hyperglycaemia. Here, in order to circumvent any
changes due to whole-body metabolism, we used a 2-week expo-
sure strategy. This allowed us to demonstrate for the first time that
fructose enhances inflammation independent of metabolic disease.
Collectively, this provides direct evidence that fructose elevates
inflammation under physiological conditions38,39.
The increase in LPS-induced inflammation from dietary fruc-
tose was not due to an enhanced global inflammatory effect, with
certain chemokines measured having no observable differences, in
addition to no effect on the mouse T cell compartment. Whether
this enhanced, fructose-mediated inflammation could contribute
to downstream pathologies warrants further investigation. For
instance, chronic fructose exposure and infection could heighten
inflammation leading to non-alcoholic steatohepatitis or carcino-
genesis12. In addition, our work using metabolic inhibitors shows
that fructose treatment leaves cells metabolically inflexible and
acutely vulnerable to further metabolic challenge. This highlights a
potential vulnerability of human monocytes exposed to fructose
when facing metabolically challenging environments, such as
during bacterial infection (including sepsis) or in the tumour
microenvironment, particularly in those individuals with a high
fructose diet.
Our results have highlighted the metabolic plasticity of human
monocytes in response to fructose exposure and have elucidated the
metabolic mechanisms supporting fructose-induced inflammation.
These findings highlight the importance of the microenvironment
Fig. 7 Fructose enhances inflammation in the presence of glucose in macrophages. A Representative TNF and IL-1β flow cytometry plots and bar graphs
of glucose (24mM) or glucose and fructose (both 12 mM) cultured mouse macrophages treated with LPS (1 ng/mL) for 5 h in the presence of
GolgiStopTM. B Schematic of 13C6-glucose (10mM) or 13C6-glucose (5 mM) and 13C1-fructose (5 mM) isotope tracing. C Hexose isotopologues, m+ 1 or
m+ 6, in mouse macrophages stimulated with LPS (1 ng/mL) for 24 h. D Glutamine uptake in the media of BMDMs cultured with 24mM glucose or 12
mM glucose and 12 mM fructose stimulated with LPS (1 ng/mL) for 0, 12 and 24 h. E Immunoblot analysis for pS6Ser235-236 in BMDMs stimulated with LPS
overnight in the presence of glucose alone or glucose/fructose. Total S6 was used as a loading control. F Cytokine production assessed by flow cytometry
and ICS for TNF, IL-1β and IL-12 of macrophages treated for 18 h with CB-839 (1 μM). G Cytokine production of TNF, IL-1β and IL-12 produced by
macrophages cultured as A with or without rapamycin (50 μM). H Schematic of in vivo experiment. Mice fed a diet of 10% glucose (n= 8) or 10%
glucose–fructose mixture (n= 7) for 2 weeks and stimulated with LPS (0.1 mg/kg) for 3 h (image of mouse obtained from Servier Medical Art). I Serum
cytokine levels of IL-1β, IL-6 and TNF. J Schematic outlining fructose metabolism promoting inflammation. mTORC1 mammalian target of rapamycin
complex 1, OXPHOS oxidative phosphorylation, TCA tricarboxylic acid. Statistical significance was assessed using an unpaired, two-tailed t test (A, I) or a
two-way ANOVA with Sidak’s multiple comparison test (D, F, G). Data are representative of five (A), two (B, C), three (D–G) or seven–eight independent
experiments (I) and are expressed as mean ± SEM. Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21461-4
10 NATURE COMMUNICATIONS |         (2021) 12:1209 | https://doi.org/10.1038/s41467-021-21461-4 | www.nature.com/naturecommunications
in shaping the innate immune response and could form the foun-
dations of investigations for therapies in areas as diverse as cancer
and infectious diseases.
Methods
Human monocyte isolation and culture. Peripheral blood was collected with
informed written consent and ethical approval was obtained from Wales Research
Ethics Committee 6 (13/WA/0190). Mononuclear cells were obtained by density
gradient centrifugation (Histopaque-1077 (10771), Merck) Human CD14+
monocytes were isolated using CD14 microbeads (130-050-201; Miltenyi Biotec).
The purity of monocytes was routinely monitored using anti-CD14 Pacific Blue
(clone 63D3; 367122; BioLegend) via flow cytometry.
Monocytes (1.0 × 106/mL) were activated with LPS (10 ng/mL; Ultrapure, tlrl-
eblps; Invivogen) and cultured in glucose (G7021) or fructose (F3510; 11.1 mM;
Merck) containing glucose-free RPMI (11879020; Thermo Fisher) supplemented
with 10% dialysed foetal bovine serum (FBS; A3382001; Thermo Fisher Scientific).
2-DG (0.1–1 mM; D8375), oligomycin (1 µM; 75351), antimycin A (1 µM; A8674)
and rotenone (1 µM; R8875) were obtained from Merck. The ACLY inhibitor,
BMS303141 (4609), was purchased from Tocris. LPS purchased from Invivogen
(Escherichia coli K12; tlrl-eklps) was used for the varying glucose concentration
experiments.
Cells were harvested and analysed for flow cytometry (acquired with
NovoExpress V1.4.1) and supernatants were stored at −20 °C for cytokine analysis.
Mice. Animal experiments were subject to ethical review by the Francis Crick
Animal Welfare and Ethical Review Body and regulation by the UK Home Office
project licence P319AE968. All mice were housed under conditions in line with the
Home Office guidelines (UK). Mice were housed 3–5 per cage and were kept in a
12-h day/night cycle 07:00–19:00. Food and water were available ad libitum and
rooms were kept at 21 °C at 55% humidity. All procedures were performed fol-
lowing the Animals (scientific procedures) Act 1986 and the EU Directive 2010.
C57/B6J mice were bred and housed at the Francis Crick Institute animal
facility. All animals used were aged 6–15 weeks and littermates were randomly
assigned to experimental groups.
Mouse BMDM differentiation and culture. Hind legs were collected from C57/B6J
mice (aged 6–15 weeks) and cleaned using a scalpel, followed by flushing of the bone
marrow with a 1mL syringe, phosphate-buffered saline (PBS) and 25 G needle. Red
blood cells were lysed using ACK lysis buffer following the manufacturer’s instruc-
tions (10× red blood cell lysis buffer, 420301; BioLegend). Bone marrow cells were
cultured on non-tissue culture-treated 10-cm Petri dishes in complete Iscove’s
modified Dulbecco’s media (IMDM), 10% FBS, 50 µM β-mercaptoethanol and sup-
plemented with 25 ng/mL of macrophage colony-stimulating factor (315-02; Pepro-
tech). BMDMs were supplemented with macrophage colony-stimulating factor every
3 days until day 7 of differentiation. BMDMs were activated with 1 ng/mL of LPS
purchased from Sigma (E. coli O111:B4 LPS25) for either 5 or 18 h according to
experiment type. Further experiments were performed with the glutaminase inhibitor
CB-839 (Merck, AMBH2D6FB23B) (1 µM per well) or rapamycin (R8781; Sigma)
(50 nM per well) with their respective vehicle controls.
Flow cytometry and intracellular cytokine staining
Human monocytes. Flow cytometry analysis was performed on monocytes after 24
h in culture. Cell death was monitored with DRAQ7 (1 µM, DR71000; BioStatus)
and DRAQ7-negative cells were analysed with anti-HLA-DR (clone AC122; 130-
095-293), anti-CD80 (clone REA661; 130-110-270), anti-CD86 (clone FM95; 130-
113-572), anti-CCR5 (clone REA245; 130-117-356) and anti-CCR2 (clone REA624;
130-109-595; all Miltenyi Biotec) and anti-CD62L (clone DREG-56; 304806;
BioLegend).
For mitochondria staining, cells were incubated with 100 nM MitoTracker
Green (M7514; Thermo Fisher) for 30 min at 37 °C. For mitochondrial membrane
potential and ROS, cells were incubated with tetramethylrhodamine ethyl ester 50
nM (ab113852; Abcam) and MitoSOX 5 µM (M36008; Thermo Fisher),
respectively, for 20 min at 37 °C. Cells were acquired (Novocyte, ACEA) and
downstream analysis was performed with FlowJo version 10 (TreeStar, USA).
Mouse macrophages. BMDMs were collected after 5 days of differentiation and
switched into 24 mM glucose IMDM or 12 mM glucose/12 mM fructose IMDM for
2 days. BMDMs were plated in either in non-TC-treated 12- or 24-well plates (1 ×
106 cells and 0.5 × 106 BMDM, respectively). Intracellular cytokine staining for IL-
12, TNF, IL-6 and pro-IL-1β (antibody details can be found below) was performed
by adding 1 ng/mL of LPS and 0.8 μL of BD GolgiStopTM per 1 mL followed by 5 h
of incubation at 37 °C.
BMDMs were scraped from the plastic and washed 1× in PBS. Surface staining
was performed for F4/80 and viability dye (Viability Dye eFluorTM 780) was used
to exclude dead cells. Cells were permeabilized, fixed, and stained with
fluorescence-conjugated anti-IL-12, TNF, IL-6 or pro-IL-1β using the
eBioscienceTM Foxp3 Transcription Factor Staining Buffer Set.
Antibodies. Fluorescence-conjugated PerCP-Cy5.5 F4/80 (clone BM8; 123128), PE
IL-6 (clone MP5-20F3; 504504) and PeCy7 IL-12/23 (clone C15.6; 505210) anti-
bodies were purchased from BioLegend. FITC-IFNγ (clone XMG1.2; 35-7311), PE-
FOXP3 (clone 3G3; 50-5773) and Violet Fluor450-CD4 (clone RM4-5; 750042)
were purchased from Tonbo Biosciences. FITC-IL-1β-pro was purchased from
Invitrogen (clone NJTEN3; 11-7114-82). TNF conjugated to APC (clone MP6-
XT22; 506308) was purchased from eBioscience Life Technologies. All antibodies
were used at a dilution of 1/300 for surface and intracellular staining.
Carboxyfluorescein succinimidyl ester stock at 5 mM was purchased from
BioLegend (423801) and used at a final concentration of 85 nM. Viable cells were
detected using the Fixable Viability dye eFluor780 (65-0865-14; eBioscience) at a
dilution of 1/1000. Samples were acquired using BD FACSDiva V8.0.1 on the BD
FACSymphonyTM Flow Cytometer and data were analysed using FlowJo V10.3
(BD). An example gating strategy can be found in the Supplementary information
(Supplementary Fig. 8).
Metabolic analysis. Metabolic analysis of monocytes was carried out using the
Seahorse Extracellular Flux Analyzer (Agilent Technologies). Monocytes (0.25 ×
106 cells) were seeded onto a Cell-Tak (354240; Corning)-coated microplate
allowing for immediate adhesion. To observe the glycolytic switch, cells were
seeded in Seahorse XF assay media supplemented with 1% foetal calf serum
(HyClone, 10703464; Fisher Scientific, USA) and 2 mM glutamine (G7515; Merck).
Monocytes were given an initial injection of glucose, fructose, galactose (G5388;
11.1 mM; Merck) or media and allowed to equilibrate. LPS (10 ng/mL; Ultrapure,
Invivogen) was injected after 1 h. To arrest glycolysis, a final injection of 2-DG
(100 mM; Merck) was added. Corresponding OCR/ECAR (oxygen consumption
rate/extracellular acidification rate) changes were monitored for the duration of the
experiment. Alternatively, monocytes were given a third injection of oligomycin (1
µM) or GSK2837808A (LDHi, 10 µM; 5189; Tocris).
For the mitochondrial stress assay, monocytes were resuspended in Seahorse XF
assay media supplemented with 11.1 mM glucose or fructose and 1 mM sodium
pyruvate (103578-100; Agilent Technologies). Injections were of oligomycin (1
µM), FCCP (3 µM), antimycin A (1 µM), rotenone (1 µM) and monensin (20 µM;
M5273; Sigma). Data were acquired using the Seahorse Wave software v2.6
(Agilent).
Enzyme-linked immunosorbent assay. IL-1β (DY201), IL-6 (DY206), IL-8
(DY208-05), IL-10 (DY217B), TNF (DY210) and prostaglandin E2 (KGE004B)
were analysed using ELISA (DuoSets; R&D Systems).
Mouse serum samples were analysed using ELISA for IL-1β (Sigma, RAB0274),
TNF (Mouse Uncoated ELISA Kit; Invitrogen, 88-7324-22), IL-6 (Mouse Uncoated
ELISA Kit; Invitrogen, 88-7064-22), CXCL1 (Raybiotech, ELM-KC-1), CXCL5
(Raybiotech, ELM-LIX-1) and CCL11 (LEGEND MAXTM, BioLegend, 443907).
ELISA plates were coated with the capture antibody and left overnight at 4 °C.
Samples were appropriately diluted and incubated for 2 h at room temperature
with gentle agitation, 2 h with the kit-specific secondary antibody and 20 min with
streptavidin-horse radish peroxidase. The plate was then incubated at room
temperature with a 1:1 mixture of hydrogen peroxide and tetramethylbenzidine
(555214; BD Biosciences). Absorbance was measured at 450 nm after the addition
of sulfuric acid (Merck) to each well and values were corrected to the blank.
Extracellular lactate measurement. Extracellular lactate was measured using the
L-Lactate Assay Kit I (120001100A; Eton Bioscience). Samples and standards were
appropriately diluted and mixed with the L-lactate assay solution and incubated at
37 °C for 30 min. Absorbance was then measured at 490 nm and concentrations
calculated from the linear regression of the standard curve.
RNA extraction and quantitative PCR of BMDMs. Total RNA was extracted
using RNeasy® columns (Qiagen) from three separate wells per condition
according to the manufacturer’s instructions. Genomic DNA was removed using
On-Column DNA digestion (Qiagen). Complementary DNA (cDNA) was gener-
ated using the High-Capacity cDNA Reverse Transcription Kit (4368814; Thermo
Fisher) according to the manufacturer’s instructions. Power upTM SYBR® Green
Master MIX (Applied Biosystem) was used to perform quantitative PCR. Primer
sequences can be found in Supplementary Table 1. Gene expression values are
calculated according to Pfaffl method40 and are expressed as relative units com-
pared to the control group. Quantitative PCR data were collected using Quant-
Studio Design & Analysis software v1.3.
RNA-seq sample preparation and sequencing. Total RNA quality and quantity
were assessed using Agilent 2100 Bioanalyser and an RNA Nano 6000 Kit (Agilent
Technologies). Sequencing libraries were prepared with 100–900 ng of total RNA with
an RNA integrity number value >8 using the Illumina® TruSeq® Stranded Total RNA
with Ribo-Zero GoldTM Kit (Illumina Inc.). The steps included ribosomal RNA
depletion and cleanup, RNA fragmentation, first-strand cDNA synthesis, second-
strand cDNA synthesis, adenylation of 3′ ends, adapter ligation and PCR amplifica-
tion (12 cycles). The manufacturer’s instructions were followed except for the cleanup
after the ribozero depletion step where Ampure®XP beads (Beckman Coulter) and
80% ethanol were used. Libraries were validated using the Agilent 2100 Bioanalyser
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and a High-Sensitivity Kit (Agilent Technologies) to ascertain the insert size, and the
Qubit® (Life Technologies) was used to perform the fluorometric quantitation. Fol-
lowing validation, the libraries were normalised to 4 nM, pooled together and clus-
tered on the cBot™2 following the manufacturer’s recommendations. The pool was
then sequenced using a 75-base paired-end (2 × 75 bp PE) dual index read format on
the Illumina® HiSeq4000 according to the manufacturer’s instructions.
RNA-seq analysis and differential gene expression. Raw sequencing files were
trimmed to remove adapter sequences and poor quality reads using TrimGalore.
Trimmed reads were aligned with the STAR aligner (v2.5.1b) to the GRCh38
assembly of the human genome41. Raw counts were then calculated using Subread
featureCounts (v1.5.1)42, and a differential expression analysis comparing glucose-
and fructose-treated monocytes was performed using DESeq2 (Bioconductor)43.
The resultant p values were corrected for multiple testing using the Benjamini and
Hochberg method44. Differentially regulated genes were defined as those with a
log2 FC > ±1 and an adjusted p value <0.05. Heatmaps were generated using
Morpheus (Broad Institute).
Immunoblot
Human monocytes. Monocyte lysate proteins were quantified, denatured and
separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Poly-
vinylidene difluoride membranes were probed with antibodies targeting HKI
(2024), HKII (2867), phospho-S6 ribosomal protein (pS6; Ser235-236; 4858),
phospho-AMPKa (2535), phospho-ACLY (4331), phospho-acetyl-CoA carboxylase
1 (3661), phospho-LDH (8176), pan-Akt (2920), phospho-AktSer473 (4060) and
phospho-AktThr308 (4056). All antibodies were purchased from Cell Signaling
(Danvers, MA) and used at a 1:1000 dilution. The total OXPHOS human cocktail
(ab110411) and GLUT5 (ab41533) were purchased from Abcam and used at a
dilution of 1:200 and 1:700, respectively. Protein loading was evaluated and nor-
malised using β-actin (ab8226; Abcam). Densitometry on non-saturated immu-
noblots was measured using ImageJ software (Fiji)45.
Mouse BMDM. Macrophages were lysed using RIPA buffer supplemented with 1%
sodium dodecyl sulfate and phosphatase inhibitors (La Roche Ltd), denatured at
95 °C, and resolved on NuPAGE polyacrylamide pre-cast gels (Thermo Fisher
Scientific) before the transfer of gels onto nitrocellulose membranes using the
iBlot2 (Invitrogen). Lysates were probed for phospho-S6 Ser235/236 (4858) ribo-
somal protein, total rpS6 (clone 54D2; 2317), phospho-AktThr308 (clone 244F9;
4056), phospho-AktSer473 (clone D9E; 4060) and pan-Akt (clone 40D4; 2920). All
antibodies were purchased from Cell Signaling Technologies. Secondary antibodies
were purchased from LI-COR IRDye 800CW (donkey anti-mouse; 926-32212) and
680LT (donkey anti-rabbit; 926-68023). Fluorescence analysis was collected using
the LI-COR Image Studio software v5.2. All original uncropped blots can be found
in the Supplementary information (Supplementary Fig. 9).
Gas chromatography-mass spectrometry. Isolated monocytes were incubated
with heavily labelled 13C5-glutamine (2 mM; CLM-1822; Cambridge Isotopes) in
RPMI phenol red-free media (Agilent Technologies) supplemented with 11.1 mM
glucose or fructose and 10% dialysed FBS (Thermo Fisher Scientific). Alternatively,
monocytes were cultured with 13C6-glucose (CLM-1396) or 13C6-fructose (CLM-
1553; 11.1 mM; Cambridge Isotopes) in glucose-free RPMI (Thermo Fisher Sci-
entific) supplemented with 10% dialysed FBS (Thermo Fisher Scientific). Mono-
cytes were activated with LPS (10 ng/mL) for 24 h, washed twice with ice-cold
saline and lysed in 80% methanol. Cell extracts were then dried down at 4 °C using
a speed-vacuum concentrator.
Cellular metabolites were extracted and analysed by GC-MS using protocols
described previously46,47. Metabolite extracts were derived using MTBSTFA (N-(tert-
butyldimethylsilyl)-N-methyltrifluoroacetamide). D-Myristic acid (750 ng/sample)
was added as an internal standard to metabolite extracts, and metabolite abundance
was expressed relative to the internal standard. GC/MS analysis was performed using
an Agilent 5975C GC/MS equipped with a DB-5MS+DG (30m× 250 µm × 0.25
µm) capillary column (Agilent J&W, Santa Clara, CA, USA). Data were acquired
using ChemStation E.02.02.1431. For SITA experiments, mass isotopomer
distribution was determined using a custom algorithm developed at the McGill
University46.
Liquid chromatography-mass spectrometry. 13C6-glucose was purchased from
Cambridge Isotope Laboratories and D-fructose-13C6 (587621) was purchased from
Sigma-Aldrich. SITA with 13C-glucose and 13C-fructose allowed for the identifi-
cation of isotopomer distribution of metabolites. Both 13C fructose and glucose
were added in glucose-free Dulbecco’s modified Eagle’s medium supplemented
with 10% dialysed FBS and 50 µM β-mercaptoethanol in the presence of LPS (10
ng/mL). Metabolites were extracted after 24 h of LPS activation and analysed by
liquid chromatography-mass spectrometry (LC-MS) using methods previously
described48. In brief, 1 × 106 BMDMs were washed with cold PBS and metabolites
were extracted with 200 µL of ice-cold extraction buffer (methanol, acetonitrile and
water (50:30:20)). Samples were centrifuged at 21.1 × g for 10 min at 4 °C and the
supernatant was collected for LC-MS analysis. Extracellular metabolites were
extracted using 10 µL of culture media added to 490 μL of ice-cold extraction buffer
and centrifuged at the aforementioned speed. Supernatants were collected and run
through LC-MS analysis. LC-MS machine information and operation is further
described in Labuschagne et al.49. Spectra analysis was performed using the
Thermo TraceFinder software.
LPS-induced systemic inflammation model. Female C57/B6J mice aged
8–10 weeks were randomly assigned either to 10% glucose water or 10% glucose/
fructose (stock solution at 60% fructose and 40% glucose) water for 2 weeks prior to
LPS challenge. Mice were injected intraperitoneally with LPS from E. coli (0111:B4;
Sigma L4391) at a dose of 0.1 mg/kg. Mice were sacrificed 3 h post challenge and
blood collected by cardiac puncture into EDTA-coated collection tubes. Blood was
spun at 2000 × g for 15 min at 4 °C and serum was collected and stored at −80 °C.
Data analysis. Statistical analysis was performed using GraphPad Prism version 9
(USA). Data are represented as the mean ± standard error of the mean with sig-
nificance taken as *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNA-seq data have been deposited in GEO under the accession code GSE164058. All
other data are available upon request or can be found within the manuscript and
Supplementary information files. Source data are provided with this manuscript.
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